Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Pharmacological treatment has been used to alleviate the claudication symptoms and improve walking performance in peripheral arterial disease (PAD) patients. However, the effects of claudication treatments on gait mechanics have not been objectively indentified with biomechanical techniques. For this study, 20 PAD patients were assigned to take either pentoxifylline (n = 11) or cilostazol (n = 9), the two FDA-approved pharmacological therapies used to treat intermittent claudication symptoms. All patients completed a gait evaluation protocol that involved the acquisition of kinematic and kinetic gait data before use of the medication and after 12 weeks of treatment. Results showed that treatment with either pentoxifylline or cilostazol resulted in limited overall improvement in gait parameters including joint angles and joint moments. Walking speed was unchanged, in either treatment group, as a result of the medication. These results suggest that to improve biomechanical walking parameters of PAD patients, clinicians cannot rely on drug therapies alone.

Original languageEnglish (US)
Pages (from-to)341-348
Number of pages8
JournalJournal of applied biomechanics
Volume26
Issue number3
DOIs
StatePublished - Aug 2010

Fingerprint

Peripheral Arterial Disease
Gait
Pharmacology
Pentoxifylline
Walking
Therapeutics
Joints
Intermittent Claudication
Mechanics
Biomechanical Phenomena
Drug Therapy

Keywords

  • Cilostazol
  • Intermittent claudication
  • Joint moments
  • Locomotion
  • Pentoxifylline

ASJC Scopus subject areas

  • Biophysics
  • Orthopedics and Sports Medicine
  • Rehabilitation

Cite this

@article{f7ee77d319504cf6adf719fa78f935b9,
title = "Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes",
abstract = "Pharmacological treatment has been used to alleviate the claudication symptoms and improve walking performance in peripheral arterial disease (PAD) patients. However, the effects of claudication treatments on gait mechanics have not been objectively indentified with biomechanical techniques. For this study, 20 PAD patients were assigned to take either pentoxifylline (n = 11) or cilostazol (n = 9), the two FDA-approved pharmacological therapies used to treat intermittent claudication symptoms. All patients completed a gait evaluation protocol that involved the acquisition of kinematic and kinetic gait data before use of the medication and after 12 weeks of treatment. Results showed that treatment with either pentoxifylline or cilostazol resulted in limited overall improvement in gait parameters including joint angles and joint moments. Walking speed was unchanged, in either treatment group, as a result of the medication. These results suggest that to improve biomechanical walking parameters of PAD patients, clinicians cannot rely on drug therapies alone.",
keywords = "Cilostazol, Intermittent claudication, Joint moments, Locomotion, Pentoxifylline",
author = "Huisinga, {Jessie M.} and Pipinos, {Iraklis I} and Nicholas Stergiou and Johanning, {Jason M}",
year = "2010",
month = "8",
doi = "10.1123/jab.26.3.341",
language = "English (US)",
volume = "26",
pages = "341--348",
journal = "Journal of Applied Biomechanics",
issn = "1065-8483",
publisher = "Human Kinetics Publishers Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes

AU - Huisinga, Jessie M.

AU - Pipinos, Iraklis I

AU - Stergiou, Nicholas

AU - Johanning, Jason M

PY - 2010/8

Y1 - 2010/8

N2 - Pharmacological treatment has been used to alleviate the claudication symptoms and improve walking performance in peripheral arterial disease (PAD) patients. However, the effects of claudication treatments on gait mechanics have not been objectively indentified with biomechanical techniques. For this study, 20 PAD patients were assigned to take either pentoxifylline (n = 11) or cilostazol (n = 9), the two FDA-approved pharmacological therapies used to treat intermittent claudication symptoms. All patients completed a gait evaluation protocol that involved the acquisition of kinematic and kinetic gait data before use of the medication and after 12 weeks of treatment. Results showed that treatment with either pentoxifylline or cilostazol resulted in limited overall improvement in gait parameters including joint angles and joint moments. Walking speed was unchanged, in either treatment group, as a result of the medication. These results suggest that to improve biomechanical walking parameters of PAD patients, clinicians cannot rely on drug therapies alone.

AB - Pharmacological treatment has been used to alleviate the claudication symptoms and improve walking performance in peripheral arterial disease (PAD) patients. However, the effects of claudication treatments on gait mechanics have not been objectively indentified with biomechanical techniques. For this study, 20 PAD patients were assigned to take either pentoxifylline (n = 11) or cilostazol (n = 9), the two FDA-approved pharmacological therapies used to treat intermittent claudication symptoms. All patients completed a gait evaluation protocol that involved the acquisition of kinematic and kinetic gait data before use of the medication and after 12 weeks of treatment. Results showed that treatment with either pentoxifylline or cilostazol resulted in limited overall improvement in gait parameters including joint angles and joint moments. Walking speed was unchanged, in either treatment group, as a result of the medication. These results suggest that to improve biomechanical walking parameters of PAD patients, clinicians cannot rely on drug therapies alone.

KW - Cilostazol

KW - Intermittent claudication

KW - Joint moments

KW - Locomotion

KW - Pentoxifylline

UR - http://www.scopus.com/inward/record.url?scp=77954139705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954139705&partnerID=8YFLogxK

U2 - 10.1123/jab.26.3.341

DO - 10.1123/jab.26.3.341

M3 - Article

C2 - 20841626

AN - SCOPUS:77954139705

VL - 26

SP - 341

EP - 348

JO - Journal of Applied Biomechanics

JF - Journal of Applied Biomechanics

SN - 1065-8483

IS - 3

ER -